ME/CFS Australia (SA) Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.
ME/CFS Australia (SA) Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.
Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.
Patients With RA, Fibromyalgia Less Likely To Achieve Remission, Low Disease Activity
Friday 30 January 2015
Patients with RA, fibromyalgia less likely to achieve remission, low disease activity
Patients with both rheumatoid arthritis and fibromyalgia were less likely to achieve remission or low disease activity scores, according to finding presented recently.
The study comprised 697 individuals with rheumatoid arthritis from the ESPOIR cohort, a 10-year follow-up study of patients with early arthritis in France. Patients were recently diagnosed with early arthritis and not had not received disease-modifying anti-rheumatic drugs. Of the 697, 120 were diagnosed with fibromyalgia (FM) at baseline.
Endpoints were compared at 6, 8 and 12 months using a mixed linear regression model of Disease Activity Score (DAS28), Simple Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI) and the Health Assessment Questionnaire (HAQ). Low disease activity and remission were analyzed with a log binomial regression at each time point.
At baseline, patients with FM had higher DAS28, SDAI, CDAI and HAQ scores than patients with RA alone, according to the researchers.
DAS28 and other disease activity scores improved to a similar extent among both patient groups, but consistently remained higher in patients with FM. The researchers found lower disease activity and remission were less likely to be achieved in patients with FM, and few would have met treat-to-target goals, they concluded. – by Shirley Pulawski
Santa Cruz, et al. Paper #1384. Presented at: American College of Rheumatology Annual Meeting. Nov. 14-19, 2014; Boston.
Disclosure: The authors have no relevant financial disclosures.
The above originally appeared here.
blog comments powered by Disqus